Breast cancer drug deemed too expensive for use in England

Kadcyla

Cancer patient explains how Kadcyla has extended her life

The National Institute for Health and Care Excellence has said women with breast cancer will not be able to have a new treatment on the NHS because it is too expensive. Kadcyla costs around £90,000 per patient and extends the lives of women with advanced forms of the disease by an average of six months.

We want to ask to all invested factory involved onto the searching treatment for breast cancer, if it is real this enormous price for medicines which has the scope to combat cancer. Are we sure on the necessity to maintain sp elevated the cost, both in production and distribution?

Rotterdam, 23/08/2014-INC News